Hoersholm; November 27, 2015 – Medical Prognosis Institute A/S (MPI.CO) (Denmark and Phoenix, AZ, USA) announced today that the prospective LungChip study has been unblinded. LungChip is a prognostic tool for predicting which patients have a good or a bad prognosis of their lung cancer, which can have impact on treatment. The study has been performed at oncology departments in USA and Denmark and data from 135 patients diagnosed with early stage 1A Non Small Cell Lung Cancer have been analyzed during the study which has been ongoing for more than five years.
After unblinding it was discovered that a rare but very aggressive sub-type of lung cancer can be identified at all stages of the disease. The LungChip prognosticator can identify those patients with the most aggressive disease making it possible to provide follow-up treatment after surgery. This aggressive type of lung cancer can only be detected with the LungChip prognosticator. If the patient is to be treated with follow-up chemotherapy – MPI’s Drug Response Prediction DRP(TM)-method can guide the choice of treatment. Further analysis with LungChip DRP(TM) has demonstrated that MPI in addition can predict which patients have a good or a bad prognosis at all later stages.
Patients from this study were diagnosed with stage 1A, Non Small Cell Lung Cancer where the tumor was smaller than 3 cm with no spreading of the disease for instance to lymph nodes so the cancer could be removed completely by surgery. In this group of patients there is a smaller fraction with a more aggressive type of cancer where adjuvant chemotherapy administered right after surgery could be considered. It is specifically these patients MPI’s LungChip prognosticator can identify.
MPI will now discuss a plan for commercialization of the new test with potential partners.
” We look forward to when MPI’s LungChip prognostic test can be offered to those identified with the most aggressive form of lung cancer enabling earlier treatment than what is available today,” says adjunct professor Peter Buhl Jensen, M.D., Ph.d., CEO in MPI. As we in addition can use MPI’s Drug Response Prediction technology – DRP(TM) to predict who will respond positively to chemotherapy, this is a unique research tool to for the treatment of lung cancer in all stages”, Peter Buhl Jensen continues.
Medical Prognosis Institute advances personalized medicine by partnering with cancer drug developers to apply its DRP(TM) diagnostic platform to streamline and de-risk clinical trials and drug development via biomarker optimization, patient stratification, and development of companion diagnostics.
About MPI’s LungChip
MPI’s LungChip genomic test is a patented tool for identification of lung cancer patients with the most aggressive disease, enabling adjuvant chemotherapy shortly after operation. The aggressive form of lung cancer can only be detected with MPI’s LungChip
About MPI’s multiple biomarker called Drug Response Predictor – DRP(TM)
MPI’s lead product, the DRP(TM) diagnostic platform, is a tool to develop tumor-derived gene signatures that may predict which cancer patients are highly likely responders to a given anticancer product. The DRP(TM) has been tested in 32 trials, where 26 trials showed that drug-specific DRP(TM) Biomarkers could predict which patients had a positive effect of the treatment. The DRP(TM) platform has also been externally validated and published in collaboration with leading statisticians at the MD Anderson Cancer Center. The DRP(TM) method can be used to design the Clinical Development Plan, i.e. to select which indications are relevant for a given anticancer drug. Further to and in addition to this, individual patients’ gene patterns can be analyzed as part of a screening procedure for a clinical trial to ensure inclusion of those patients who have a high likelihood of response to the drug. The DRP(TM) platform can be used in all cancer types and has been patented for more than 60 anticancer drugs in the US.
For further information, please contact
Peter Buhl Jensen, CEO
Cell Phone: +45 21 60 89 22
Certified Advisor: Carsten Yde Hemme, PricewaterhouseCoopers, Strandvejen 44, 2900 Hellerup, Denmark